• SHARE

The health ministry on Monday approved a monoclonal antibody-based treatment developed by GlaxoSmithKline PLC and U.S. firm Vir Biotechnology Inc., the second time it has given its OK to a drug for the treatment of mildly and moderately ill COVID-19 patients.

Sotrovimab, which is given as a single dose intravenously, became the fifth medicine approved in Japan for treating COVID-19.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)